Hemangiosarcoma: Advancing canine cancer treatment with targeted therapies
Canine cancer diagnoses can be devastating and demoralizing. While research and studies for human cancer have brought us a long way when it comes to treatment and instilling hope for our loved ones, the same can’t necessarily be said for the world of pet medicine. Despite this, there are many passionate veterinarians and veterinary oncologists […]
Splenic Hemangiosarcoma Case Study: Pita
With a combination approach that included FidoCure® therapy, Pita lived for a year following a hemoabdomen and diagnosis of splenic hemangiosarcoma.
Research featured in The Cancer Letter
We were thrilled to see our recent Nature paper featured in last week’s issue of The Cancer Letter! Our multi-year study has compared canine and human cancer journeys and revealed predictive biomarkers and beneficial therapeutics that impact both sides of the leash. We are honored to be recognized in The Cancer Letter, a leading publication for oncology professionals […]
TCC Case Study: Sir Oliver
Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from FidoCure™ enrollment, Sir Oliver’s latest CT scan showed a 38% reduction in his bladder tumor.
Mammary Carcinoma Case Study: Missy
After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.
Squamous Cell Carcinoma Case Study: Duchess
It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time with minimal disease progression, and having an overall positive impact on patient care.
Lung Carcinoma Case Study: Adley Hurwitz
After six months of FidoCure® enabled therapy, Adley showed no evidence of pulmonary mass recurrence.
Hemophagocytic Histiocytic Sarcoma Case Study: Forrest
A 11 yr old Golden with hemophagocytic histiocytic sarcoma, 38 months in remission. FidoCure® identified a rare tumor suppressor mutation and suggested additional therapy that may have helped target tumor cells.
Thyroid Carcinoma Case Study: Lulu
After more than 20 months of FidoCure® enabled treatment, Lulu has remained free from further metaseses. There has been no evidence of disease recurrence or pulmonary metastasis. Lulu has maintained a positive quality of life while in treatment and achieved extended time with her pet owners.
Splenic Hemangiosarcoma Case Study: Sam
After FidoCure® enabled treatment, Sam exceeded the 5-7 month median survival time for splenic hemangiosarcoma by living over one year beyond diagnosis.
